SLC5A2 and chronic kidney disease: Importantly, this study was conducted entirelyremotely—patients were enrolled and monitored with only virtual visits, and nonew safety signals were identified.59 Meta-analysis ofcardiovascular outcome trials (CVOTs) has demonstrated reductions inhospitalization for HF associated with SGLT2 inhibitor treatment in patientswith T2D, including those with and without CKD, and in patients with CKDregardless of T2D status.6,7,60,61 Reductions in subsequenthospitalizations with SGLT2 inhibitor treatment have also been demonstrated forpatients with acute decompensated HF.62